5T4 oncofetal antigen is expressed in high risk of relapse childhood pre-B acute lymphoblastic leukemia and is associated with a more invasive and chemotactic phenotype.
Authors
Castro, Fernanda VMcGinn, Owen J
Krishnan, S
Marinov, Georgi
Li, J
Rutkowski, A J
Elkord, Eyad
Burt, Deborah J
Holland, M
Vaghjiani, R
Gallego, A
Saha, V
Stern, Peter L
Affiliation
Cancer Research UK Immunology Group, Paterson Institute for Cancer Research, University of Manchester, Manchester, UK.Issue Date
2012-01-23
Metadata
Show full item recordAbstract
Although the overall prognosis in childhood acute lymphoblastic leukemia (ALL) is good, outcome after relapse is poor. Recurrence is frequently characterized by the occurrence of disease at extramedullary sites, such as the central nervous system and testes. Subpopulations of blasts able to migrate to such areas may have a survival advantage and give rise to disease recurrence. Gene expression profiling of 85 diagnostic pre-B-ALL bone marrow samples revealed higher 5T4 oncofetal antigen transcript levels in cytogenetic high-risk subgroups of patients (P<0.001). Flow cytometric analysis determined that bone marrow from relapse patients have a significantly higher percentage of 5T4-positive leukemic blasts than healthy donors (P=0.005). The high-risk Sup-B15 pre-B-ALL line showed heterogeneity in 5T4 expression, and the derived, 5T4(+) (Sup5T4) and 5T4(-) (Sup) subline cells, displayed differential spread to the omentum and ovaries following intraperitoneal inoculation of immunocompromised mice. Consistent with this, Sup5T4 compared with Sup cells show increased invasion in vitro concordant with increased LFA-1 and VLA-4 integrin expression, adhesion to extracellular matrix and secretion of matrix metalloproteases (MMP-2/-9). We also show that 5T4-positive Sup-B15 cells are susceptible to 5T4-specific superantigen antibody-dependent cellular toxicity providing support for targeted immunotherapy in high-risk pre-B-ALL.Leukemia advance online publication, 17 February 2012; doi:10.1038/leu.2012.18.Citation
5T4 oncofetal antigen is expressed in high risk of relapse childhood pre-B acute lymphoblastic leukemia and is associated with a more invasive and chemotactic phenotype. 2012:LeukemiaJournal
LeukemiaDOI
10.1038/leu.2012.18PubMed ID
22266911Type
ArticleLanguage
enISSN
1476-5551ae974a485f413a2113503eed53cd6c53
10.1038/leu.2012.18
Scopus Count
Collections
Related articles
- CD9, a key actor in the dissemination of lymphoblastic leukemia, modulating CXCR4-mediated migration via RAC1 signaling.
- Authors: Arnaud MP, Vallée A, Robert G, Bonneau J, Leroy C, Varin-Blank N, Rio AG, Troadec MB, Galibert MD, Gandemer V
- Issue date: 2015 Oct 8
- Targeting the 5T4 oncofetal glycoprotein with an antibody drug conjugate (A1mcMMAF) improves survival in patient-derived xenograft models of acute lymphoblastic leukemia.
- Authors: McGinn OJ, Krishnan S, Bourquin JP, Sapra P, Dempsey C, Saha V, Stern PL
- Issue date: 2017 Jun
- IL7R is associated with CNS infiltration and relapse in pediatric B-cell precursor acute lymphoblastic leukemia.
- Authors: Alsadeq A, Lenk L, Vadakumchery A, Cousins A, Vokuhl C, Khadour A, Vogiatzi F, Seyfried F, Meyer LH, Cario G, Hobeika E, Debatin KM, Halsey C, Schrappe M, Schewe DM, Jumaa H
- Issue date: 2018 Oct 11
- The expression of stem cell protein Piwil2 and piR-932 in breast cancer.
- Authors: Zhang H, Ren Y, Xu H, Pang D, Duan C, Liu C
- Issue date: 2013 Dec
- Human t(1;19)(q23;p13) pre-B acute lymphoblastic leukemia in mice with severe combined immunodeficiency.
- Authors: Uckun FM, Downing JR, Gunther R, Chelstrom LM, Finnegan D, Land VJ, Borowitz MJ, Carroll AJ, Crist WM
- Issue date: 1993 Jun 1